Loading…
← CockpitCompetitor Analysis › BIO Bio-Rad Laboratories, Inc. Class AOpen in the cockpit ↗

Bio-Rad Laboratories, Inc. Class ABIOCompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties

Maker of life-science research reagents/instruments (PCR, chromatography) and clinical diagnostics test systems.

Momentum strong 78
Mkt cap
$10.1B
US dollars, full cap
Free float
82%
of shares outstanding
$/day
$96.9M
20-day average traded
Fwd P/E
34.6×
forward earnings
ROIC−WACC
-7.1 pp
WACC 9.8%
Hurdle
+26 pp
Req g minus delivered
Official | Implied
BBB / BBB
agencies · bond market
Next earnings
92 days
18 Feb 2027
Close · USD$370.17
1D+3.3%
1W-4.1%
1M+4.4%
3M-1.7%
6M+28.6%
YTD+22.2%
1Y+21.7%
ATR %3.3%
Beta0.71
52w lowhigh6.6% off high

What Bio-Rad Laboratories does

Maker of life-science research reagents/instruments (PCR, chromatography) and clinical diagnostics test systems.

Sells instruments to labs and then earns repeatedly on the reagents and quality-control materials they use, which gives recurring revenue. Clinical diagnostics is the bigger segment. The company holds a large stake in Sartorius, a German lab-equipment maker, which produces large unrealized gains or losses in reported profit. The Schwartz family controls the votes through Class B shares.

Products and services

  • Life Science (PCR, digital PCR, protein analysis)
  • Clinical Diagnostics (quality controls, testing systems)

Customers

  • Academic/government research labs
  • Clinical diagnostic labs
  • Biopharma companies

Where it sits in the supply chain

  • Healthcare/Life Sciences
  • Life science tools & diagnostics
  • Research reagents/instruments and…

What could go right

  • Genomics/digital PCR adoption growth
  • Clinical diagnostics QC market share

What could go wrong

  • Academic/government research funding cycle sensitivity
  • Earnings volatility from its large Sartorius equity stake

Moat: narrow (installed base, switching costs, IP / patents). Digital PCR and diagnostics quality-control franchises have loyal, workflow-embedded customer bases.

Headquarters: Hercules, California, USA · Founded: 1952 · Employees: 7,450

Named competitors

Bio-Rad Laboratories at a glance

Size Bio-Rad Laboratories (BIO) is a United States Health Care company (Medical Specialties) with a market value of $10.1B, the 763rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $370.17 on 18 Nov 2026.

Performance Over six months the shares gained 28.6%, against +30.7% for the median peer and -2.2% for the United States market (cap-weighted) — 11th highest of 21 in its peer set.

Growth Revenue grew 1.4% over the last twelve months (peer median +7.2%); the operating margin is 9.5% (peer median 14.6%).

Valuation It trades at 34.6× forward earnings against a peer median of 19.9× (4th most expensive of 21).

Price implies For today's price to make sense, revenue must grow about 26% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +26 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 7.1 points below its cost of capital (9.8% WACC).

Credit Bio-Rad Laboratories has 2 bonds outstanding ($1.20B), rated BBB by the agencies and trading like BBB at a weighted spread of 106 bp.

Short interest Short interest is 5.3% of the free float (30 Oct 2026).

Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 2026Peer median 130BIO 129
Six months, rebased to 100: Bio-Rad Laboratories against the median of its 20 peers (local-currency closes).

Bio-Rad Laboratories financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$2.59B$2.58B$2.57B$2.67B$2.80B
Revenue growth—+1%-4%-5%—
Gross profit$1.35B$1.34B$1.38B$1.43B$1.57B
EBITDA$450M$472M$504M$576M$657M
Net income$1.02B$760M-$1.84B-$637M-$3.63B
Free cash flow$329M$375M$289M$218M$1.32B
Capital expenditure$139M$158M$166M$157M$114M
Total debt$1.36B$1.39B$1.38B$1.41B$1.40B

Quarterly statements and history in the cockpit →

Bio-Rad Laboratories competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%+60%-10%0%+10%+20%QGENDEMANTPODDAVTRBRKRGMEDCOOALGNBIM77016869SNPEN300832BAXGETI-BLENSKARTBLCOGKOSBIO6-month return →1-month return →
Up and to the right = strong over both horizons. Bio-Rad Laboratories is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%+30%50×100×QGENDEMANTPODDAVTRBRKRGMEDCOOBIM6869PEN7733BAXGETI-BLENSKARTGKOSBIORevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Bio-Rad Laboratories is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%QGENDEMANTPODDAVTRBRKRGMEDCOOALGN77016869PEN7733300832BAXGETI-BLENSKARTBIOGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Bio-Rad Laboratories is the large dot.

Bio-Rad Laboratories competitors and peer comparison

Head to head with its named competitors (BIO vs TMO vs DHR vs TECH)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Bio-Rad Laboratories BIO$10.1B+29%+1%9%34.6×26.0%
Thermo Fisher Scientific TMO$257B+53%+8%19%25.7×21.3%
Danaher DHR$161B+34%+6%21%25.1×20.8%
Bio-Techne TECH$11.4B+56%+1%21%34.4×31.6%

How Bio-Rad Laboratories compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Bio-Rad Laboratories against its 20 peers (data as of 18 Nov 2026)
MeasureBIOPeer medianRank in peer set
1-month return+4.4%+6.1%10th lowest of 21
6-month return+28.6%+30.7%11th highest of 21
Distance from 52-week high-6.6%-11.7%5th highest of 21
Revenue growth (TTM)+1.4%+7.2%4th lowest of 21
Operating margin9.5%14.6%5th lowest of 21
Forward P/E34.6×19.9×4th most expensive of 21
Growth the price implies (Req g, 7 yrs)26.0%9.4%3rd most demanding of 20
Growth delivered (Del g)+0.3%+10.0%2nd lowest of 20
Hurdle (Req g minus delivered)+25.7 pp+2.0 ppmost demanding of 20
ROIC minus cost of capital-7.1 pp+2.4 pp2nd lowest of 21
EV / EBITDA21.7×12.4×3rd most expensive of 19
Net debt / EBITDA-0.7×0.9×3rd least indebted of 19
Bond spread106 bp113 bptightest of 5

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Bio-Rad Laboratories BIOUnited States$10.1B+29%+1%9%34.6×26.0%+0.3%
Qiagen QGENUnited States$10.2B+41%+2%25%19.5×8.6%+2.2%
Demant A/S DEMANT.CODenmark$10.4B+39%+10%18%23.2×5.8%+9.8%
Insulet PODDUnited States$9.71B-11%+26%18%18.6×10.6%+24.5%
Avantor AVTRUnited States$10.4B+95%+1%8%17.5×16.4%+0.5%
Bruker BRKRUnited States$9.66B+43%+2%10%27.0×25.4%+11.6%
Globus Medical GMEDUnited States$9.34B-16%+13%23%13.7×4.6%+30.1%
Cooper Companies (The) COOUnited States$11.6B-2%+5%19%13.4×9.4%+11.0%
Align Technology ALGNUnited States$11.6B0%+4%19%13.8×13.1%+10.3%
bioMerieux BIM.PAFrance$11.8B+26%-3%15%20.2×8.6%+5.5%
Shimadzu 7701.TJapan$8.14B+24%+8%14%21.0×8.3%+7.3%
Sysmex 6869.TJapan$8.06B+58%+8%13%32.0×4.4%+10.4%
Smith & Nephew SN..LUnited Kingdom$12.6B+1%+2%17%14.2×11.1%+5.6%
Penumbra PENUnited States$12.6B-2%+17%12%55.7×30.7%+20.2%
Olympus 7733.TJapan$12.7B+5%+9%18%18.7×-6.5%+6.7%
Shenzhen New Industries Biomedical Engineering 300832.SZChina$7.50B+21%+7%43%26.9×2.9%+15.7%
Baxter International BAXUnited States$13.5B+39%+5%6%12.7×13.4%-0.7%
Getinge GETI-B.STSweden$7.45B+40%-4%14%21.1×5.0%+3.2%
Lenskart Solutions LENSKART.NSIndia$13.6B+49%+35%10%137.7×53.2%+33.5%
Bausch + Lomb BLCO.TOCanada$7.41B+35%+11%9%18.3×12.0%+10.0%
Glaukos GKOSUnited States$13.8B+62%+47%-9%161.5×n/an/a

Bio-Rad Laboratories bonds and credit

Bio-Rad Laboratories has 2 bonds outstanding with $1.20B face value. The agencies rate it BBB; its bonds trade like BBB. Weighted yield 5.75%, a spread of 106 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Bio-Rad Laboratories's main competitors?
Named competitors: Thermo Fisher Scientific (TMO), Danaher Corporation (DHR), Bio-Techne (TECH). The cockpit's measured peer set (industry) also includes Qiagen (QGEN), Demant A/S (DEMANT.CO), Insulet (PODD), Avantor (AVTR), Bruker (BRKR), Globus Medical (GMED).
Is Bio-Rad Laboratories expensive compared with its peers?
On forward p/e it trades at 34.6× against a peer median of 19.9×, 4th most expensive of 21 in its peer set. For today's price to make sense, revenue must grow about 26% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +26 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Bio-Rad Laboratories stock performed?
Over six months to 18 Nov 2026 the shares returned +28.6% against +30.7% for the median peer; over one year +21.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.